STLNNasdaqServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31Also trades as DFPH, STLNW
Starling Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$6.46+0.03 (+0.47%)
Close on Oct 19, 2026
- Market cap
- $665.58M
- P/E (TTM)
- –
- Dividend yield
- –
Starling Oncology statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Services-Offices & Clinics of Doctors of Medicine companies for comparison
Valuation
| Measure | Starling Oncology | Industry median |
|---|---|---|
| Market Cap | $658.38M | $1.11B |
| Enterprise Value | $697.15M | $1.41B |
| PS Ratio | 1.12 | 1.60 |
| P/OCF Ratio | 2007.25 | 15.44 |
Enterprise value
| Measure | Starling Oncology | Industry median |
|---|---|---|
| EV / Sales | 1.19 | 1.69 |
Income (trailing twelve months)
| Measure | Starling Oncology | Industry median |
|---|---|---|
| Revenue | $587.24M | $561.90M |
| Operating Income | -$26.09M | -$1.81M |
| Pretax Income | -$36.29M | -$572.42K |
| Net Income | -$36.29M | -$1.16M |
| EBITDA | -$19.28M | -$20.72K |
| EPS (Diluted) | -$0.30 | -$0.02 |
Margins
| Measure | Starling Oncology | Industry median |
|---|---|---|
| Operating Margin | -4.44% | -4.45% |
| Pretax Margin | -6.18% | 1.54% |
| Profit Margin | -6.18% | -2.91% |
| EBITDA Margin | -3.28% | 2.41% |
| FCF Margin | -0.56% | 3.13% |
Returns
| Measure | Starling Oncology | Industry median |
|---|---|---|
| Return on Assets (ROA) | -21.5% | -3.06% |
| Return on Invested Capital (ROIC) | -83.1% | 2.11% |
| Return on Capital Employed (ROCE) | -31.3% | -0.57% |
Growth
| Measure | Starling Oncology | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 38.4% | 6.92% |
| Revenue Growth (3Y CAGR) | 25.8% | 10.9% |
| Revenue Growth (5Y CAGR) | 21.8% | 13.2% |
Balance sheet
| Measure | Starling Oncology | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $41.09M | $48.71M |
| Total Debt | $79.87M | $140.00M |
| Net Cash (Debt) | -$38.77M | $205.49K |
| Net Cash Per Share | -$0.38 | $0.01 |
| Equity (Book Value) | -$24.91M | $235.16M |
| Book Value Per Share | -$0.24 | $3.48 |
| Tangible Book Value | -$41.73M | $703.69K |
| Working Capital | $34.05M | $30.48M |
Financial position
| Measure | Starling Oncology | Industry median |
|---|---|---|
| Current Ratio | 1.36 | 1.40 |
| Quick Ratio | 1.13 | 1.02 |
| Interest Coverage | -3.42 | -0.63 |
Cash flow (trailing twelve months)
| Measure | Starling Oncology | Industry median |
|---|---|---|
| Operating Cash Flow | $328.00K | $3.10M |
| Capital Expenditures | -$3.61M | -$18.62M |
| Free Cash Flow | -$3.29M | $23.73M |
| FCF Per Share | -$0.03 | $0.37 |
Efficiency
| Measure | Starling Oncology | Industry median |
|---|---|---|
| Asset Turnover | 3.47 | 0.87 |
| Revenue Per Employee | $916.14K | $228.48K |
| Profits Per Employee | -$56.62K | -$5.75K |
| Employee Count | 641 | 910 |
Dividends and yields
| Measure | Starling Oncology | Industry median |
|---|---|---|
| Earnings Yield | -5.51% | -0.59% |
| FCF Yield | -0.50% | 1.74% |
Shares
| Measure | Starling Oncology | Industry median |
|---|---|---|
| Shares Outstanding | 101,916,000 | 58,282,400 |
| Shares Change (YoY) | 25.6% | 2.68% |
| Shares Change (QoQ) | 0.50% | 0.32% |
| Float | 44,256,800 | 33,780,100 |
| Shares Held by Insiders | 56.6% | 16.4% |
| Shares Held by Institutions | 43.4% | 85.9% |
Taxes
| Measure | Starling Oncology | Industry median |
|---|---|---|
| Income Tax | $0 | $697.00K |
Scores
| Measure | Starling Oncology | Industry median |
|---|---|---|
| Altman Z-Score | 2.76 | 2.05 |
| Piotroski F-Score | 3 | 5 |
Calculated by StockData from Starling Oncology's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.